Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

A randomized double-blinded placebo-controlled trial involving 268 male COVID-19 outpatients showed that proxalutamide, an androgen receptor antagonist, significantly reduced the rate of hospitalization. Over a 30-day period, the hospitalization rate was 2.2% for the proxalutamide group compared to 26% for the placebo group, representing a 91% reduction. No deaths were reported in the proxalutamide group, while 2 deaths occurred in the placebo group. However, gastrointestinal adverse events were more frequent in the proxalutamide group. The study suggests proxalutamide could be a potential treatment option for COVID-19 in men, but further studies are recommended.